NCT05273827

Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium

Clinical Observation of the Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium in Patients With Non-small Cell Lung Cancer

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 81 (actual)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To observe the effect of preoperative anti-PD-1 monotherapy combined with chemotherapy on patients' perioperative pain and opioid analgesia, and evaluate its effect on the incidence and severity of patients' postoperative delirium.

Detailed description

In this study, the investigators intend to select patients with resectable NSCLC treated with immuno-neoadjuvant therapy in combination with chemotherapy, systematically observe the effect of preoperative anti-PD-1 monotherapy on patients' perioperative pain and opioid analgesia, and evaluate its effect on the incidence and severity of patients' postoperative delirium, in order to provide a clinical basis for the perioperative management of patients treated with immuno-neoadjuvant therapy and promote their postoperative recovery.

Conditions

• Immunotherapy
• Analgesia
• NSCLC
• Delirium

Interventions

Type	Name	Description
DRUG	neoadjuvant immunotherapy	Anti-PD-1 antibody was added to the conventional neoadjuvant chemotherapy.
DRUG	Neoadjuvant chemotherapy	Cis-platinum combined with paclitaxel or pemetrexed

Timeline

• Start date: 2022-03-22
• Primary completion: 2023-12-20
• Completion: 2024-01-02
• First posted: 2022-03-10
• Last updated: 2024-01-05

Locations

3 sites across 1 country: China